Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119186 | 0.96 | PDE5A (1.00) | PDE5APDE6C | |
| Hydrochloric Acid SCHEMBL6359398 | 0.95 | PDE5A (0.98) | PDE5APDE6C | |
| SCHEMBL7616279 | 0.93 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL6776828 | 0.93 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6771870 | 0.92 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6776131 | 0.92 | PDE5A (0.86) | PDE5APDE6C | |
| SCHEMBL119755 | 0.91 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL2407731 | 0.90 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6774758 | 0.89 | PDE5A (0.88) | PDE5APDE6C | |
| SCHEMBL6773582 | 0.89 | PDE5A (1.00) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1149579-B1 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | PFIZER PROD INC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040122010-A1 | Treatment of neuropathy | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| US-20030105114-A1 | Methods of treatment and kits comprising a growth hormone secretagogue | CARPINO PHILIP A (US) | 2003-06-05 | — | — | US | disclosed |
| US-20030083228-A1 | Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction | CARPINO PHILIP A (US) | 2003-05-01 | — | — | US | disclosed |
| EP-1285658-A2 | Treatments for female sexual dysfunction | Pfizer Productors Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| US-6512002-B2 | Treating timidity and enhancing libido in postmenopausal women, or treating male sexual dysfunction by administering to a patient in need thereof an effective amount of an estrogen agonist/antagonist | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020173502-A1 | Pharmaceutically active compounds | PFIZER INC | 2002-11-21 | — | — | US | disclosed |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | JAMES HARRIS LAURENCE (GB) | 2002-08-15 | — | — | US | disclosed |
| US-6407259-B1 | REACTING DIETHER COMPOUND WITH ACYLATING AGENT COMPRISING ACID ANHYDRIDE OR ACID HALIDE DERIVATIVE TO FORM PYRAZOLE DERIVATIVE | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | PFIZER INC. | 2002-02-21 | — | — | US | disclosed |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122010-A1 | Treatment of neuropathy | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 9/4885 |
| US-20020173502-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 20/4885 |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885PDE6C 4116/4885 |
| US-20030083228-A1 | Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction | MC1R, MCHR2, MC3R | PDE5A 208/4885PDE6C 607/4885 |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | PDE5A 4/4885PDE6C 11/4885 |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885PDE6C 4116/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6C 20/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6C 20/4885 |
| US-20030105114-A1 | Methods of treatment and kits comprising a growth hormone secretagogue | GIPR, GHSR, GHRHR | PDE5A 48/4885PDE6C 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.